Supply chain configuration conundrum: how does the pharmaceutical industry mitigate disturbance factors? by Huq, Fahian Anisul/FAH et al.
Huq, Fahian Anisul/FAH and Pawar, Kulwant S. and 
Rogers, Helen (2016) Supply chain configuration 
conundrum: how does the pharmaceutical industry 
mitigate disturbance factors? Production Planning & 
Control, 27 (14). pp. 1206-1220. ISSN 1366-5871 
Access from the University of Nottingham repository: 
http://eprints.nottingham.ac.uk/41471/1/TPPC-2016-0026Huq%20et%20al%20PPC
%20Pharma%20manuscript_final%20post%20acceptance.pdf
Copyright and reuse: 
The Nottingham ePrints service makes this work by researchers of the University of 
Nottingham available open access under the following conditions.
This article is made available under the University of Nottingham End User licence and may 
be reused according to the conditions of the licence.  For more details see: 
http://eprints.nottingham.ac.uk/end_user_agreement.pdf
A note on versions: 
The version presented here may differ from the published version or from the version of 
record. If you wish to cite this item you are advised to consult the publisher’s version. Please 
see the repository url above for details on accessing the published version and note that 
access may require a subscription.
For more information, please contact eprints@nottingham.ac.uk
1 
 
 
Supply Chain Configuration Conundrum: How does the 
Pharmaceutical Industry Mitigate Disturbance Factors?           
Fahian Huq, Kulwant S Pawar and Helen Rogers 
 
 
 
Name:  Dr Fahian Anisul Huq 
Institution: Manchester Business School,  
Address: Marketing, Operations Management and Service Systems Division 
Room 3.67 MBS West, 
Booth Street West,  
Manchester M15 6PB, U.K.  
E-mail: fahian.huq@mbs.ac.uk  
 
Name:  Professor Kulwant S Pawar 
Institution: Centre for Concurrent Enterprise  
Address: Nottingham University Business School,  
University of Nottingham, 
Jubilee Campus,  
Nottingham,  
NG8 1BB, U.K. 
E-mail: Kul.Pawar@nottingham.ac.uk 
 
Name:  Professor Helen Rogers 
Institution: Technische Hochschule Nuernberg/University of Applied Sciences 
Address: 90402 Nuernberg,  
Deutschland 
E-mail: Helen.Rogers@th-nuernberg.de 
 
Corresponding author: Professor Helen Rogers 
[Corresponding Author’s Email] Helen.Rogers@th-nuernberg.de 
 
 
 
  
2 
 
Supply Chain Configuration Conundrum: How does the 
Pharmaceutical Industry Mitigate Disturbance Factors?           
Production Planning & Control 
http://dx.doi.org/10.1080/09537287.2016.1193911  
 
Abstract 
How a supply chain (SC) is configured can have a significant impact on the performance of global 
firms. More specifically, disturbance factors (i.e. those factors associated with uncertainty and risk) 
are increasingly important considerations. This paper focuses on endogenous, exogenous and 
environment-related SC disturbance factors and their relative importance when configuring global 
SCs. Three alternative scenarios of SC configurations for European-based pharmaceutical firms are 
identified - insource nearshore, outsource nearshore and outsource offshore. Through a multi-phase, 
mixed-method approach we find that the top five disturbance factors managers should be aware of 
while configuring their SCs are quality defects, unforeseen and random interruptions in 
manufacturing processes, order processing difficulties, untimely delivery of products, and a 
mismatch between market demand and supplier responsiveness. This study is able to provide 
insights into the impact of disturbance factors on the SC configuration strategy for Big Pharmas. 
We show that SC disturbances influenced the decision to bring production back home (reshoring) 
or to a closer location (near-shoring). To mitigate the effects of disturbances many Big Pharmas 
recalibrated their SC configurations by insourcing core products, outsourcing non-core products 
offshore and developing offshore insourcing capabilities through ‘captives’. 
 
Keywords: supply chains; pharmaceuticals, disturbance; risk, outsourcing, reshoring  
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1. Introduction  
Leading Western pharmaceutical manufacturers, the so-called Big Pharmas (BPs), have 
experienced high turnover from ‘blockbuster’ drugs, long patent lives and high returns on 
investments. However, this scenario is rapidly changing, as the billion-dollar ‘blockbusters’ are 
coming off patent and the BPs are struggling to develop new medicines to replace them (PWC, 
2007; Skibo, 2013). Declining R&D productivity and profits coupled with an increasingly 
competitive global market have led to seek ways to reduce production and material costs by 
outsourcing to cheaper locations, creating increasingly complex and more global supply chains 
(Peck, 2005; Zsidisin et al., 2005; Taps and Steger-Jensen, 2007). This in turn has caused BPs to 
focus on their core competencies such as R&D while outsourcing non-core functions to contract 
manufacturing organisations (CMOs) in low-cost emerging economies. This has been particularly 
evident in terms of the manufacture of generic drugs or those coming off patent (Enyinda et al., 
2009; Marucheck et al., 2011). A further trend has been the sourcing of both active and inactive 
ingredients from developing (lower cost) countries. For example, AstraZeneca outsourced 
manufacturing of a key ingredient in one of its best-selling drugs to a CMO in China (Wall Street 
Journal, 2007). It also has dedicated sourcing centres in China (Shanghai) and India (Bangalore).  
By implementing globally complex supply chains - where sourcing, manufacturing, 
packaging and distribution may occur at different locations - the potential for supply chain 
disturbances, i.e. risks and uncertainties, increases. This in turn can lead to lost market value, 
product recalls, regulatory actions, etc. (McKinsey, 2012) For example, in 2008 Baxter Healthcare 
was obliged to recall batches of heparin following 81 deaths associated with the product 
(Bloomberg, 2008). The US Food and Drug Administration (FDA)’s subsequent investigation led 
to the identification of ten suppliers of the Active Pharmaceutical Ingredient (API), the chemicals 
used to produce heparin, which had been manufactured in China and shipped to eleven countries 
(FDA, 2008). The quality and safety measures of the Chinese suppliers were found to be inadequate, 
placing the entire supply chain at risk (The Chartered Quality Institute, 2012). Johnson & Johnson 
lost over $900 million in revenue in 2010 owing to supply chain disturbances related to 
manufacturing and quality issues (New York Times, 2011). In 2009 its Tylenol product was recalled 
following consumer reports of gastrointestinal symptoms, believed to have been caused by a 
chemical used to treat wooden transportation pallets produced in the Dominican Republic (Rogers, 
2010). These cases show that incidents can occur at all levels within the supply chain and any 
disturbances can potentially threaten patients’ lives. Against this backdrop, the aim of this paper is 
to identify supply chain disturbance factors for pharmaceutical firms and to assist managers in 
deciding on the most appropriate supply chain configuration, given the level of disturbances in their 
supply chains. Three alternative SC configurations are investigated (a) insource nearshore, (b) 
outsource nearshore and (c) outsource offshore.  
2. Literature Review 
2.1 Supply Chain Disturbances in the Pharmaceutical Industry 
Although many authors have sought to categorise risk and uncertainty in the supply chain context 
(Davis, 1993; Mason-Jones and Towill, 1998; Jüttner et al., 2003; Spekman and Davis, 2004; 
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Jüttner, 2005; Peck, 2005; Rogers et al., 2012; Simangunsong et al., 2012), the two terms are still 
often used interchangeably (Pawar and Rogers, 2013). Despite the similarities, and even though 
both are forms of organisational disturbances, Rogers et al. (2012) preferred to distinguish between 
them by pointing out that risk has a probabilistic factor associated with it (Spekman and Davis, 
2004) while uncertainty is a condition in which it becomes difficult to predict the likelihood of 
various future events (Srinivasan et al., 2011). Researchers have identified the following 
dimensions of risk and uncertainty – demand, supply, process, control, environment, location and 
national/business culture (Davis, 1993; Mason-Jones and Towill, 1998; Christopher and Lee, 2004; 
Jüttner, 2005; Wright and Albores, 2010).  
 Supply chain disturbances result in poorer performance on metrics such as inventory costs, 
efficiency of communication, lead time and responsiveness, as well as profitability and shareholder 
value (Hendricks and Singhal, 2005; Hendricks et al., 2009). Despite this the topic has so far 
received limited research attention (Bode et al., 2011; Simangunsong et al., 2012). Decisions on 
where to locate have primarily been based on cost measures, neglecting other factors such as internal 
and external supply chain-related disturbances (MacCarthy and Atthirawong, 2003; Tate et al., 
2009). The trend towards outsourcing and in particular offshore manufacturing (Bhatnagar and 
Sohal, 2005; Peck, 2005; Zsidisin et al., 2005; Christopher and Holweg, 2011) has increased 
vulnerability to a range of disturbances such as hurricanes, earthquakes, political instability, etc. 
(Chopra and Sodhi, 2004, 2014; Craighead et al., 2007; Ellis et al., 2011) and economic factors such 
as wage inflation in lower cost countries (Simchi-Levi, 2010; Wagner and Neshat, 2012). 
Pharmaceutical MNC supply chain vulnerability to disturbances was exposed by the 2011 Japanese 
earthquake and tsunami that led to (among many other serious problems) interruptions in the supply 
of glycine, an ingredient for solid-dosage products and the gelatine used in soft gel capsules (Miller, 
2011). It is challenging for companies with complex multi-tiered supply chains to manage all 
potential disturbances, and to date there has been limited research on this topic. Chen and Hung 
(2010) developed one of the first outsourcing manufacturing partner selection models for the 
pharmaceutical industry using an integrated fuzzy approach. Marucheck et al. (2011) identified 
safety challenges that arise in highly regulated industries, including problems of contamination, 
counterfeiting and secondary distributors in the pharmaceuticals industry. Gray et al. (2011) is the 
only paper identified that studied risk in the pharma supply chain using primary data. However, 
their focus was on the comparison of internal quality risk between onshore and offshore locations. 
Thus, a gap remains in terms of understanding the disturbances present in different supply chain 
configurations using empirical data and how they can be mitigated.  
For this paper, by conducting an extensive literature review, sources of pharma-related 
supply chain disturbances were identified and grouped into endogenous (firm-related), exogenous 
(network-related) and environmental (location-related) disturbance factors. This is summarised in 
Table 1. Endogenous disturbance factors are related to the focal firm and include internal process 
(e.g. manufacturing processes, quality) and control (order processing, information flow) 
disturbances. Exogenous disturbance factors occur within the supply chain network, i.e. the focal 
firm and its partners, and comprise demand (e.g. mismatch between market demand and supplier 
responsiveness, difficulty in demand forecasting), supply (untimely delivery of products, 
mismatched inventory levels) and control (difficulty communicating with suppliers or transmitting 
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data) disturbances. Environmental disturbances are related to the firm’s choice of sites or 
manufacturing partners and include relative production costs; hidden costs of distant operations 
(e.g. increased lead times); geopolitical issues (man-made/natural disasters, societal disruptions, 
political instability); accessibility of logistics provision (road, sea and air freight services); 
reliability of energy (power), internal transport and telecommunication infrastructure; skills, 
education level and talent of the labour force; cultural differences; and Intellectual Property Rights 
(IPR) risks.  
 
 
Endogenous 
Factors 
Description  Key Literature 
Process 
disturbance  
Unforeseen and/or random interruptions that 
significantly affect operations e.g. machine 
break downs, quality defects etc. 
(Davis, 1993; Mason-Jones and Towill, 1998; Geary, 
2002; Van Der Vorst and Beulens, 2002; Christopher 
and Peck, 2004; Bhatnagar and Sohal, 2005; Sheffi and 
Rice, 2005; Lockamy et al., 2008) 
Control 
disturbance 
Breaks in information flow that convert 
customer orders into production targets and 
supplier raw material requisition. 
(Mason-Jones and Towill, 1998; Wilding, 1998; Geary, 
2002; Christopher and Peck, 2004; Prater, 2005) 
 
Exogenous 
Factors 
  
Demand 
disturbance  
Difference between the actual end 
marketplace demand and orders placed 
within an organisation by customers e.g. the 
‘bullwhip effect’. 
(Davis, 1993; Fisher, 1997; Mason-Jones and Towill, 
1998; Prater et al., 2001; Van Der Vorst and Beulens, 
2002; Christopher and Peck, 2004; Prater, 2005; 
Lockamy et al., 2008) 
Supply 
disturbance 
Disruptions e.g. due to quality, 
environmental, health or safety issues 
leading to untimely delivery of products or 
mismatched inventory levels. 
(Davis, 1993; Mason-Jones and Towill, 1998; Prater et 
al., 2001; Geary, 2002; Lee, 2002; Van Der Vorst and 
Beulens, 2002; Zsidisin, 2003a, b; Christopher and 
Peck, 2004; Prater, 2005; Lockamy et al., 2008) 
Control 
disturbance 
Associated with the interruption of 
information flow throughout the supply 
network rather than only the firm itself. 
(Davis, 1993; Evans et al., 1993; Mason-Jones and 
Towill, 1998; Wilding, 1998; Geary, 2002; Christopher 
and Peck, 2004) 
 
Environmental 
Factors 
  
Relative 
production 
costs per region 
Comparative cost of labour, transport and 
energy per region, productivity cost of 
dispersed production systems. 
(Carter and Narasimhan, 1996; MacCarthy and 
Atthirawong, 2003; Simchi-Levi, 2010; Porter and 
Kramer, 2011) 
Hidden costs of 
distant 
operations 
Increased physical distances increase 
complexity and uncertainty leading to 
hidden costs of distant operations. 
(Prater et al., 2001; Van Der Vorst and Beulens, 2002; 
Simchi-Levi, 2010; Porter and Kramer, 2011) 
Geopolitical 
Issues 
Geopolitical factors can generally be 
classified as governmental, natural and 
societal disruptions. 
(Prater et al., 2001; Chopra and Sodhi, 2004; 
Christopher and Peck, 2004; Bhatnagar and Sohal, 
2005; Hendricks and Singhal, 2005; Jüttner, 2005; 
Peck, 2005; Chan et al., 2008; Knemeyer et al., 2009; 
Ellis et al., 2011) 
Accessibility of 
logistics  
Availability and quality of land, sea and air 
freight services. 
(Prater et al., 2001; Peck, 2005; Wu et al., 2007; 
Simangunsong et al., 2012) 
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Infrastructure 
 
Availability and reliability of land, power, 
transport and telecoms infrastructure. 
(Prater et al., 2001; Bhatnagar and Sohal, 2005; Chan 
et al., 2008; Simangunsong et al., 2012) 
Labour force 
quality 
Skill, education level, productivity and 
availability of labour force. 
(MacCarthy and Atthirawong, 2003; Bhatnagar and 
Sohal, 2005) 
Cultural factors 
 
Issues of trust, bureaucracy, corruption, 
ethics, etc. leading to misunderstandings. 
(Wilding, 1998; Hofstede, 2001; Van Der Vorst and 
Beulens, 2002; Rogers et al, 2015) 
Intellectual 
Property Rights 
(IPR) 
Potential risk of infringement of IPR due to 
outsourcing. 
(Cockburn et al., 2007; Pawar and Rogers, 2013) 
Table 1: Disturbance Factors affecting Pharmaceutical Supply Chain   
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2.2 Mitigating Disturbances through Supply Chain Re-configuration 
Increasingly, large multinational firms, in an effort to simultaneously provide local responsiveness 
and global integration, are developing complex, differentiated supply chains which increases the 
likelihood of disturbances (Mizgier et al., 2015b). The complex and dynamic interactions between 
supply chain entities leads to considerable disturbances that can propagate up and down the supply 
chain - adversely affecting performance (Bhatnagar and Sohal, 2005; Blackhurst et al., 2007). Such 
disturbances can significantly reduce operational performance, profitability and shareholder value 
over the long term (Hendricks and Singhal, 2005; Hendricks et al., 2009). To counter such negative 
effects, various supply chain disturbance mitigation strategies have been examined in the research 
literature, mainly comprising of demand management (e.g. demand shaping), supply management 
(e.g. having strategic stock or a flexible supply base), product management (e.g. postponement), 
process improvements (e.g. quality control), supply chain integration (e.g. vendor managed 
inventory) and capital adequacy (e.g. through insurance cover) strategies (Tang, 2006; Mizgier et 
al., 2015a; Wiengarten et al., 2016). Even though at the macro level, supply chain configuration is 
one of the principal strategic supply decisions which can help multi-national firms mitigate the 
disturbances brought about by today’s dynamic business environment, it has only received limited 
attention in previous research (Tang and Musa, 2011; Mizgier et al., 2012). That is why, it is 
important to understand how disturbances can be mitigated through supply chain re-configuration. 
What makes this more challenging is the fact that there is no ‘one-size-fits-all’ supply chain strategy 
and even the supply chain configuration of firms making similar products might differ due to some 
unique characteristics (Simchi-Levi, 2010). 
 As global markets are becoming increasingly competitive, firms are under immense pressure 
to reduce production and material costs, especially during difficult economic climate. In order to 
reduce costs firms have resorted to outsourcing their production to cheaper locations. Outsourcing 
can be off-shore i.e. the relocation of a firms manufacturing or other processes (distribution, 
business services, R&D etc.) to a foreign land to take advantage of less costly operations there or it 
can be nearshore i.e. the location is at a closer proximity to the country of origin than the off-shoring 
site e.g. Eastern European countries are near-shoring sites for Western European based firms, 
whereas India and China are off-shoring sites. However, the idea that location no longer matters 
and the cheaper the location the better, is increasingly being challenged due to a greater recognition 
of the total cost of highly dispersed supply chains and hidden costs of distance (Porter and Kramer, 
2011). Thus, the inherent disturbances present in extended supply chains are causing firms to review 
their supply chain configuration (Mizgier et al., 2015b). As a consequence, some firms are actively 
considering reshoring and some, despite higher labour costs, have already started to bring a certain 
portion of production closer to home i.e. insource nearshore (Ellram et al., 2013). This ability to 
reconfigure key elements of the supply chain, as an alternative permutation from the current state 
can enable improvements in the supply of the product and help mitigate disturbances (Srai and 
Gregory, 2008). In this paper the relevant supply chain (re)configuration strategies available to large 
pharmaceutical firms to mitigate disturbance factors is identified. As most prior disturbance 
mitigation research does not take the characteristics of different industry specific supply chains into 
consideration (Wagner et al., 2014), this research aims to fill the knowledge gap concerning how 
BPs can reconfigure their supply chains to mitigate disturbances. 
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3. Methodology  
The key focus of this research is Big Pharmas (BPs) whose headquarters are in Europe but have a 
global presence in branded products and manufacturing sites in multiple countries. Big Pharma is 
defined here as those pharmaceutical firms with revenues in excess of $20 billion. Currently nine 
firms in the world meet this criteria, and of those, five have their headquarters in Europe 
(Fiercepharma, 2013). Our study was longitudinal in nature, spanning five years (2010-15) and 
mainly focussed on two European-based BPs, which from now on are referred to as BP1 and BP2. 
Views from other BPs were incorporated via the participation of executives, e.g. Director Global 
Sourcing (BP3, Europe), VP (BP4, US) and the Head of R&D (BP5, Europe), in three workshops.  
3.1 Research Design: Multi-phase, Mixed Methods Approach 
A multi-phase, mixed-methods approach was used to address the research objective of providing 
insights into the types of disturbances in the pharmaceutical supply chain and their mitigation 
strategies through supply chain reconfiguration (Onwuegbuzie and Collins, 2007; Bazeley, 2008). 
According to Saunders et al. (2009), the two key advantages of mixed methods are that it can be 
used for different purposes and it enables triangulation. Initially, relevant articles on supply chain 
disturbances (including supply chain risk, uncertainty and disruptions) were identified through 
searches of the Business Source Premier, ProQuest and Emerald databases. Analysis of selected 
papers led to the development of the preliminary list of disturbance factors. In the subsequent phases 
(Section 2.2), primary data was collected using mixed methods via workshops, semi-structured 
interviews, surveys, site visits in (UK/China/India); personal observations and firms’ internal 
reports (see Figure 1). These multiple sources strengthened the analysis by allowing triangulation 
on important issues to cross-verify insights and findings. The intent of using such a multi-phase, 
mixed methods approach was to maximise the opportunity to observe relatively more completely 
the phenomenon, thereby gaining more robust insights.  
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Figure 1: Research Design: Multi-stage, mixed-method approach 
- Workshops 1 & 2: 
SC Executives from 
Big Pharmas, 
academics, members 
of professional 
bodies and 
consultants  
- Identification of the 
different supply chain 
configurations of BPs 
and their disturbance 
factors. 
 
- Site visits in the UK, 
China and India; 
- Face-to-face semi-
structured interviews with 
12 senior SC Executives in 
Big Pharma1 
- Workshop 3 
- Ranking of disturbance 
factors from internal 
survey of relevant experts 
in Big Pharma 1&2, 
leveraged through 
interview data and 
complemented with 
company and consultancy 
reports  
Literature 
Review 
Analysis of results 
and validation of 
conceptual model 
Identification of 
SC configurations 
and disturbance 
factors 
Phase Three 
Phase Two 
Twotage 
Phase One 
Operationalization 
of disturbance 
factors 
- Key word search in 
business databases  
- Abstract analysis 
- Full paper analysis 
- Initial list of 
disturbance factors 
- Analysis and validation of 
results through follow-up 
interviews 
- Understanding drivers of 
current SC configuration 
and disturbance 
mitigation strategies 
through five elite 
interviews with the Senior 
Supply Chain Executives 
- Conceptual model 
-  
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3.2 Data Collection and Analysis 
A three-phase empirical study involving different data sources and data collection methods was 
conducted. The supply chain is our unit of analysis as it is appropriate for the study of supply 
chain-wide disturbances and provides a more systematic and holistic understanding of the 
phenomena (Harland et al., 2003; Craighead et al., 2007). In Table 2, the timeline of the study, 
comprising year, location, data collection method and participant profile, is presented. Phase I 
entailed two highly participative and intensive three-hour focus group workshops held in India 
and China in 2011 with senior pharmaceutical executives - including participants from 
European and US-based BPs, academics, members of professional associations and industry 
consultants. Information was recorded by note taking, and afterwards a summary of the main 
points was circulated among the participants for validation. Through these workshops we were 
able to identify the different supply chain configurations of BPs and their disturbance factors. 
 
Year & 
Location 
Data Collection 
Method (of 
interviews) 
Participants/Interviewees (Designation)  
2011 India Focus Group 
Workshop 1 
12 senior executives from the pharmaceutical industry - including 
participants from the Europe based Big Pharma (BP) 1 & 2; 
Director Global Sourcing of BP3 (Europe); VP of BP4 (US);  
Senior Members of the Organisation of Pharmaceutical Producers 
of India (OPPI) Global Sourcing Committee; Professors from 
MIT, Indian Institute of Management & Nottingham University. 
P
h
a
se
 I
 
2011 China Focus Group 
Workshop 2 
18 senior executives from the pharmaceutical industry & 
academics e.g. Senior Manager Sourcing – BP1; Manager - 
Supplier of BP1 & academics from UK, USA & the Chinese 
European International Business School. 
2011-12 UK Interview (x4) Global Outsourcing Manager (BP1) 
P
h
a
se
 I
I 
2011-12 UK Interview (x2) Supply Chain Director (BP1) 
2011-12 
China 
Interview (x2) Senior Manager Sourcing  (BP1) 
2012 China Interviews (x4) Interviews with 4 senior executives of BP1 based in Shanghai 
responsible for sourcing and managing suppliers. 
2012 India Interviews (x3) Managing Director, Outsourcing Project Manager and Senior 
Project Manager of BP1 based in  India 
2012 UK Interview (x2) VP for Supply Chain (BP1, UK) and VP for R&D (BP1, UK) 
2012 India Workshop 
(approx.50 
attendees) 
Attendees consisted of high profile speakers, including managers 
from BP1 & BP5 (US) and Indian pharma suppliers/CMOs, 
academics from UK & India and government officials.   
2013 UK Questionnaires Questionnaires were sent to 11 key SC executives based in the 
European headquarters of BPs 1 & 2, responsible for the design, 
planning and managing of the SC with an average of 7 years of 
experience.  
2013-15 UK Interviews in BP1 Senior Director, Supply Chain Management (x2) 
Global Outsourcing Manager (x2) 
Sourcing Director (x1) P
h
a
se
 
II
I 
Table 2: Timeline of the Study, Data Collection Methods and Participant Profile 
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In Phase II (2011-13), we studied in detail the global supply chain of Europe-based 
BP1. By focusing on a single firm, in-depth information pertaining to the supply chain 
disturbance factors was obtained. In line with case study guidelines (Yin, 2009), we conducted 
site visits in the UK, China and India and also carried out seventeen face-to-face semi-
structured interviews with twelve senior executives, each lasting approximately an hour. 
Detailed notes were taken and then analysed along with the firm’s internal reports, which 
enabled us to refine the final list of twenty disturbance factors. A third workshop was held in 
India where the challenges faced by BPs in a global context were discussed and debated. 
Participants included managers from BP1 and BP5, Indian pharma suppliers/CMOs, academics 
(UK and India) and government officials. Highlights focused around discussions on trends and 
developments in managing pharma supply chains at the regional, national and international 
level; comparative analysis of outsourcing destinations such as India and China and their 
implications for supply chain design; and finally comparisons of various supply chain 
configurations and their related disturbance factors.  
We then went on to operationalise the disturbance factors in the different supply chain 
configurations by testing them in BP1 and BP2. As it is difficult to directly quantify 
“disturbance”, a 5-point Likert scale was developed with the aim of assigning appropriate 
weights to the disturbance factors. The questionnaire comprised twenty questions relating to 
twenty disturbance factors, and respondents rated the level of disturbance in the three alternate 
supply chain scenarios. This was sent to eleven key supply chain European-based executives 
of BP1 and BP2, requesting that they rank the disturbance factors. Seven usable questionnaire 
responses were then analysed. The survey data was used to calculate weights for the individual 
disturbance factors, weights of disturbance factors across the different supply chain 
configurations and the total weight of disturbance in alternative supply chain configurations. 
The combined feedback consisting of the conceptual expertise of leading researchers and the 
experience of industry from the workshops, along with our interview data were leveraged to 
further support the ranking of disturbance factors. These were also complemented by relevant 
company and consultancy reports. 
In Phase III (2012-15), five elite interviews were conducted with the Senior Supply 
Chain Director, Sourcing Director and Senior Outsourcing Manager dealing with suppliers in 
Europe, India and China of BP1. ‘Elite’ refers to managers with significant decision-making 
influence who can provide substantial meaning to a particular situation (Harvey, 2011). This 
revealed current trends in supply chain configuration strategies of BPs, their disturbance 
mitigation strategies and how possible future configuration models might look, given the 
disturbance factors. Furthermore, through these follow up interviews our ranking of 
disturbance factors was validated and it provided us with additional data to further strengthen 
the robustness of our weighting process.  
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4. Findings 
4.1 Three supply chain configuration scenarios  
Phase I led us to identify the following three supply chain configurations (relevant for a large 
R&D-based MNC headquartered in Europe but with a global presence and multiple locations 
across the world): insource nearshore, outsource nearshore, and outsource offshore. These were 
used as a basis for discussion with BP supply chain executives. As with all models, some 
simplifications and aggregations are made, resulting in depicting the model as a single, 
“generic” component (Davis, 1993). Accordingly, while building the various supply chain 
configuration models, the summarised characteristics of the aggregated parts were checked 
against expert opinion to ensure they adequately represent the situation. For example, as R&D 
remains the pharmaceutical MNCs’ core competency and their desire to retain control for 
sustained competitiveness, it has been assumed that the R&D is carried out in Europe. It has 
also been assumed that in all three supply chain designs the raw materials are sourced from 
China. The markets considered outside Europe were Asia and Africa, owing to their high 
growth rates. North America was not considered as it is a mature market with low growth rate. 
In the following sections, the three different supply chain scenarios are presented in turn.  
4.1.1 Insource nearshore (Europe) 
Nearshore insourcing occurs when almost all activities take place in the country of origin 
(Europe) and there is no outsourcing (Erber and Sayed-Ahmed, 2005; Lalwani et al., 2007). 
As extended supply chains bring with them increased risks, focal firms need to evaluate their 
supply chain designs to make informed decisions regarding in-house or closer to home 
production options, i.e. insource. In this research, an MNC based in Western Europe is 
considered as the focal firm. Thus, in the first supply chain configuration, R&D is carried out 
in Europe, raw materials are sourced from China and the manufacturing [Active 
Pharmaceutical Ingredient (API) and formulation] and subsequent packaging are carried out in 
Europe. From there it is transferred to a central distribution centre and transported to the 
customers (see Figure 2). 
 
 
Figure 2: Insource Nearshore (Europe) 
4.1.2 Outsource nearshore (Eastern Europe) 
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Nearshore outsourcing implies that certain operations are outsourced to partner firms within 
Europe, and here we assume that one of the options for European MNCs is to locate to low-
cost Eastern European countries. The United Nations Statistics Division (2013) defines Eastern 
European countries as Belarus, Bulgaria, Czech Republic, Poland, Russia, Slovakia, Ukraine, 
Romania, Hungary and Moldova. Pharmaceutical firms view manufacturing in Eastern Europe 
as attractive for several reasons; it has been identified as an emerging market by BPs such as 
Astra Zeneca (2010) and Pfizer (2010); it has highly educated and low-cost labour; and it has 
cultural similarities, a good knowledge of languages, solid technical skills and minimum 
regulatory problems for Western European firms (AT Kearney, 2005). While designing this 
supply chain configuration, R&D is considered to be taking place in Europe and the raw 
materials are sourced from China. The difference to the previous model is that all the 
manufacturing (API and formulation) is carried out in Eastern Europe, i.e. the supply chain 
strategy is nearshore outsourcing. Packaging takes place in a central European location to cater 
to the comparatively higher demand and stricter regulations of the larger advanced economies. 
From there it is transferred to distribution centre A (located in Europe), which serves customers 
in Europe and Africa, and distribution centre B (located in Asia), which serves customers in 
Asia (see Figure 3). Both distribution centres have the option to customise packaging according 
to the needs of the target location. 
 
Figure 3: Outsource Nearshore (Eastern Europe) 
 
4.1.3 Outsource offshore (India/China) 
Offshore outsourcing occurs when parts of the value chain are transferred to firms outside the 
parent firm’s national borders and the site is comparatively remote (Erber and Sayed-Ahmed, 
2005; Lalwani et al., 2007). The third option is to outsource part of the manufacturing to Asia 
(specifically India/China). As Europe grapples with rising R&D costs and declining drug 
outputs and as governments attempt to contain spiralling healthcare outlays, European 
pharmaceutical firms have been exploring emerging markets that offer a low-cost structure 
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along with other potential benefits, such as sizeable domestic markets and opportunities for 
clinical-trial licensing (KPMG, 2011). Regulations also play a part e.g. in China it is quicker 
to register new drugs if some part of the development and/or manufacturing has taken place in 
China. This makes it strategically attractive to locate sourcing and manufacturing functions in 
Asia, as reflected in Figure 4, where the firms follow the strategy of offshore outsourcing to 
Asia. After packaging the goods in Asia, they are transported to two distribution centres; one 
in Europe (distribution centre A) catering to European and African markets and the other in 
Asia (distribution centre B), serving the Asian market.  
 
Figure 4: Outsource Offshore (India/China) 
5. Disturbance factors and mitigating strategies 
In this section we describe how the ranks have been arrived at, followed by specific issues 
pertaining to endogenous, exogenous and environmental disturbances. We then outline the 
mitigating strategies adopted by the pharmaceutical firms. The data from Phase II was used to 
calculate weights for the individual disturbance factors, weights of disturbance factors across 
the different supply chain configurations and the total weight of disturbance in alternative 
supply chain configurations, rather than provide statistically significant results. These rankings 
informed subsequent discussions with ‘elite’ interviewees in Phase III. By incorporating 
interviewees’ perspectives, we were able to gain practical insights into different disturbance 
factors and explore the strategies deployed to mitigate them.  
5.1 Disturbance factor 
The calculated weight for each disturbance factor, representing its relative importance (and 
adding up to one), is shown in Table 3. This table reveals the top three most important 
disturbance factors are all related to internal process disturbances (endogenous) at the 
outsourcee/supplier firm, i.e. quality defects, unforeseen and random interruptions in 
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manufacturing processes and difficulty in order processing. In contrast, the experts considered 
the disturbances created by reliability of energy (power), internal transport and 
telecommunication infrastructure; quality of skills, education level and talent of the labour 
force and natural disasters as least important – all three being environmental disturbance 
factors. This can be interpreted as follows: if a pharmaceutical sourcing professional has 100 
minutes to devote to the list of disturbance factors, then he/she would spend approximately 
6.34 minutes ensuring product quality (the highest ranked factor) and only 3.86 minutes on the 
issue of reliability of energy (power), internal transport and telecommunication infrastructure 
(the lowest ranked factor). This emphasises the relative importance of disturbances caused by 
quality defects, as compared to reliability of energy (power), internal transport and 
telecommunication infrastructure, or on a broader scale the importance of internal 
(endogenous) disturbances as compared to site/location (environmental) related disturbances. 
By ranking the weights, the most important disturbance factors can be identified, allowing 
additional time to be spent to improve these. 
 
Rank Disturbance Factors Weight (%) 
1 Quality defects  6.343 
2 Unforeseen and random interruptions in manufacturing processes 6.145 
3 Difficulty in order processing 6.145 
4 Untimely delivery of products 6.145 
5 Mismatch between market demand and supplier responsiveness 6.046 
6 Inaccurate demand forecasting 5.946 
7 Problems communicating with your trading partners 5.748 
8 Break in information flow 5.451 
9 Costs of distant production 5.055 
10 Societal disruptions/strikes 4.559 
11 Risk of infringement of IPR 4.559 
12 Level of political instability 4.460 
13 Quality of skills, education level and talent of the labour force 4.460 
14 Difficulty in transmitting data 4.361 
15 Disparity in national cultures  4.262 
16 Mismatched inventory levels 4.262 
17 Accessibility of logistics provision 4.163 
18 Natural disasters  4.063 
19 Quality of skills, education level and talent of the labour force  3.964 
20 Reliability of energy (power), internal transport and 
telecommunication infrastructure 
3.865 
 Total Percentage 100 
Table 3: Weight of Disturbance Factors 
 
All interviewees from Phase III agreed that quality defects were the most important 
disturbance factor. According to the Sourcing Director of BP1, patient safety is the single most 
important factor. He explained that between10-20 chemical transformations must occur to 
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convert the raw material to the active ingredient. BP1 has a rigorous audit system to inspect 
supplier quality, including environmental health and safety audits.  
 
The overall weight of each supply chain configuration (Figure 5) shows that the supply 
chain disturbance in Asia has the highest value (39.94%), followed by Eastern Europe 
(32.90%) and Western Europe (27.16%). Firms generally enter markets they understand and 
where perceived uncertainty is low, and it is expected that supply chain disturbances will be 
lower in regions with less possibility of political unrest or natural disasters. This tendency is 
reflected in these results, which show environmental disturbances faced by the focal 
pharmaceutical firm with a manufacturing base in Western Europe have the lowest weight 
(10.8%), whereas in Eastern Europe it is 14.5% and in Asia 18.1%. Moreover, in Western 
Europe, the endogenous and exogenous disturbance factors are on average lower when 
compared to both Eastern Europe and Asia, which is most likely due to the advantages of less 
distant (less complex) supply chain configurations and better process control. 
 
 
Figure 5: Overall Percentage Weights of Disturbance for alternative SC Configurations  
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 The weights of each of the 20 disturbance factors are displayed in Figure 6. Owing to space limitations, 10 factors have been highlighted 
for discussion (three endogenous, three exogenous and four environmental) in the following sections.  
 
 
 
Figure 6: Ranking of Relative Weights of Disturbance Factors within the three Alternative SC Configurations 
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5.1.1 Endogenous disturbances 
 Quality defects were the top disturbance factor for Western and Eastern Europe. One of 
the interviewees pointed out they avoid suppliers who flout the rules and don’t operate 
safely: “From our perspective, quality is king, geographical area doesn’t matter. Quality 
is the major concern.” In fact as per the view of the Senior SCM Director of BP1, cost 
takes a firm second place to quality. For example, Chinese suppliers are required to 
possess minimum levels of technical and compliance capability. Cost savings are 
present but relatively modest: they are on average only 30-40% cheaper to their Western 
European counterparts. Cheaper Chinese suppliers are available but are not worth the 
risk. 
 
 Unforeseen and random interruptions are important for all three locations. In Eastern 
Europe the risk is energy supply interruptions. For example, the 2009 Russia–Ukraine 
gas dispute led to Russia halting gas flow through Ukraine, completely cutting off 
supplies to South Eastern Europe for 13 days, much of which was completely reliant 
on Russian gas. On the other hand, power breakdowns in Asia are common, making 
backup generators a basic must have for an organisation’s operating strategy. In Asia 
there are increased chances of other random unexpected interruptions occurring, e.g. 
labour strikes or taking holidays at short notice to attend weddings. In line with this, a 
Senior Supply Chain Director commented: “Overall we see more unplanned 
disturbance from Asia generally.” These can cause big disruptions and disturbances in 
the entire supply chain with the cumulative effects being significant. 
 
 Difficulty in order processing is also highly ranked. When sourcing from or 
manufacturing in distant regions, problems due to non-standardised systems (e.g. units 
of measurement), misunderstandings, disparity of cultures and traditions (e.g. language, 
religion, festivals, etc.) can occur. Reasons differ but can lie within the processes 
themselves, technical systems and/or communication issues. Translating orders from 
one language to another can cause miscommunication, as can non-standardised 
procedures for order processing, e.g. using commas instead of dots when entering 
numbers in a spreadsheet. Furthermore, incompatibilities of technical standards, 
procedures and processes remain an issue. 
 
5.1.2 Exogenous disturbances 
 Communication problems rank 4th (relatively high) within Western Europe. This is 
counterintuitive as one would expect lower levels of miscommunication when 
suppliers/manufacturing units are closer to home.  Communication is always a factor in 
supply chain management, and the lack of it will always contribute to increased 
exposure to disturbance.  
 
 Inaccurate demand forecasting: The longer the supply chain, the greater the demand 
forecasting difficulties due to unreliable data, coupled with a lack of historical trends 
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and projections. The Sourcing Director of BP1 agreed, especially when a new drug 
compound is under development: “If you have overestimated on how much you want, 
it is easy to turn it off and use that facility for something else. It is less easy if you 
underestimate… if the capacity is not there you cannot just magically find it elsewhere.” 
The degree of unpredictability is especially high in Asia with confidence levels low, a 
point confirmed by a Senior Manager of BP: “Demand forecasting is currently much 
better in Western markets when compared to Asian regions.” 
 
 Difficulty in transmitting data was rated very low in Western Europe (19) and Eastern 
Europe (18), while in Asia it was mid-ranking (11). A case in point arose with BP1, 
whereby the Sourcing Director explained the situation with a (terminated) Indian 
supplier: “The supplier was pumping effluents into the river. These should have been 
treated as there was a potential risk of heavy metal contamination, as well as active 
pharmaceutical ingredients. The analysis of the effluent was monitored by a third party 
and rather than reporting the high metal level, they were diluting the samples and then 
analysing so that they all passed. When the government agency re-analysed the 
samples, they found that the effluent levels were ten times higher! The third-party 
auditor admitted the dilution practice…whereby they effectively falsified batch records 
and were lying about the products being made… Basically significant risks still exist in 
India regarding data integrity. This is known to the FDA who have raised concerns 
about classification of data at Indian companies.”  
5.1.3. Environmental disturbances 
  National cultural differences: Although the Supply Chain Director from BP1 agreed 
with most of the weights, he would “rank cultural differences higher in Asia”, 
emphasising that despite globalisation, cultural differences remain a challenge for 
managers dealing with distant suppliers. He considered that Western partners are “able 
to understand their business better”. Regarding relations with Indian suppliers “It is not 
only about the capability, it is also about the leadership. It depends on the support you 
get from senior management…” Interestingly, when we interviewed BP1’s executives 
during Phase II (2011-12), they were developing India as an outsourcing hub, but by 
Phase III (2015) they were scaling down their operations in India and shifting orders to 
China. The difference in attitude between BP1’s Indian and Chinese suppliers was 
further demonstrated by its Sourcing Director: “…India has a very innovative 
culture…but suppliers spend a lot of time and effort working around the rules rather 
than within them. Chinese suppliers are very compliant - one can almost guarantee that 
they will follow the standard operating procedures.” Interestingly, he noted that the 
Chinese government’s role in enforcing regulation played a large part in standards 
compliance. According to him, the Melamine Scandal of 2008 whereby milk products 
were poisoned with melamine, leading to infant deaths and widespread sickness was a 
turning point for Chinese manufacturers – “7-8 years ago we wouldn’t outsource any 
of the final stages or indeed anything that comes into contact with the patient….the 
melamine scandal was a wakeup call. We have seen over time that Chinese standards 
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have vastly increased. When I look at the standard of their factories (now), they are 
where Western Europe was 12-15 years ago. They are catching up very quickly.” 
 
 Hidden costs of distant production: The Sourcing Director agreed that cost is a key 
driver in terms of where to outsource for long-term competitiveness. Even though cost-
attractive suppliers are considered, the cheapest price is not always the best due to 
hidden costs associated with distant production. For example, dealing with complex 
chemistry requires close support from the BP. Travel from Europe to Asia to 
troubleshoot problems is time consuming and costly. Furthermore “if a problem occurs 
in Western Europe, I can guarantee to get someone there within two days, it can take 
twice as long to Asia”. Some pharmaceutical products have a short shelf life requiring 
constant temperature control, especially if the product is an injectable liquid, e.g. 
insulin, for which a temperature of 2-8 degree Celsius must be maintained. To ensure a 
stable state when outside temperatures reach 30-35 degree Celsius is a major challenge, 
especially when shipping drugs across the Indian Ocean. Incorporating the required 
temperature controls incurs cost into the BP’s logistics operations. Even regional 
differences in temperature within countries are not to be underestimated. For instance, 
winter temperatures in Northern China can dip to minus 30 degrees Celsius while in 
Southern China it is 20 degrees Celsius. Without careful planning, this variation 
provides scope for supply chain disruption. 
 
 Societal disruptions arising man-made disasters, can potentially lead to disturbances. 
The deadly explosions in the port of Tianjin, China in August 2015, which also 
devastated large areas of the city, are a case in point. The initial blast took place at a 
port warehouse containing hazardous and flammable chemicals (BBC, 2015). This 
explosion impacted one of BP1’s Chinese suppliers, whose plant was situated just 800 
metres from the main explosion. BP1s Sourcing Director elaborated on the gravity of 
such disruptions: “(Since the blast) the supplier is not allowed to produce and the 
government is unhappy with the safety standards in the city, meaning we can’t get 
material from that supplier which has a knock-on effect on our supply chain”. 
 
 Intellectual Property Rights (IPR) infringement risk: Looking across the three different 
configurations, there is little overlap in terms of the ranking of the key disturbance 
factors – except for IPR issues between Asia and Eastern Europe. According to the BP1 
Sourcing Director, disturbances from the risk of IPR infringement is “very high in their 
list”. The risk of drugs being counterfeit is also present, especially in China. There has 
been a proliferation of such activities and some high-profile cases e.g. counterfeit 
version of the cancer drug Avastin entering the US medical supply chain via online 
drug sales. These (cheaper) counterfeit drugs are re-packaged and sold in Western 
markets through Internet sites. BP1 is installing product security features (e.g. RFID 
tags and packaging holograms) in response. BP1 has also lobbied the Chinese 
government to bring penalties for selling counterfeit drugs in line with those for 
recreational drugs, which are currently much stricter. China is “showing promise in 
terms of rebranding of IPR compared to five years ago” (BP1). 
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5.2 Mitigation strategies 
Our findings indicate firms tackle supply chain disturbances by implementing the appropriate 
configuration. The right configuration will assist with enhancing supply chain performance, 
conversely a wrong choice will hinder performance. The objective should be to (re)design the 
supply chain for optimal performance, in line with supply chain objectives, while reducing the 
potential for disturbances. As this longitudinal study developed over a five year period, we had 
a unique opportunity to observe how disturbances were mitigated through recalibration of 
BP1’s supply chain configurations. Indeed, three important recalibrations emerged: 
5.2.1 Reshoring/nearshoring core products: 
The first trend to emerge was reshoring/nearshoring of products, more specifically the 
insourcing of core products. In 2010, when we initiated this project, BPs were focused on 
outsourcing manufacture of both core and non-core drugs to cheaper locations with similar skill 
sets. BP1s Sourcing Director reminisced: “In 2007 we decided we wouldn’t manufacture much 
of the material ourselves. So we closed down most of our facilities and knew we could buy the 
raw materials much cheaper externally.” This situation changed drastically within 5 years as 
described by the Global Outsourcing Manager: “By 2010 there was a different approach to 
supply chain configuration. We are now focussing on core products (patented, high revenue 
drugs) and non-core products (generic). For out-patented non-core products we are looking 
at Asia and Eastern Europe - sourcing where labour is cheaper. Core products are usually 
sourced or manufacture from our core hubs (in Western Europe). This was not my answer five 
years ago, now we have multiple strategies.” From its outsourcing experience of the past 10 
years, BP1 realised it needed to have better control over its core products, as well as potential 
blockbuster drugs in the pipeline. Getting the product into the market at the right time is very 
important for core products because profit margins are very high. 
BP1s Sourcing Director admitted that disturbance factors also influenced their decision 
to bring production back home (reshoring) or to a closer geography (nearshoring). This was 
due to both external (e.g. the Tianjin explosion) and internal events (e.g. the Indian supplier 
falsifying environmental data). After thorough investigations BP1 judged that poor data 
integrity (data transmission problems) from Indian suppliers was too high and thus ceased 
carrying out core functions in India. The Sourcing Director predicted additional significant 
investments in developing BP1’s internal drug manufacturing capability.  
5.2.2 Outsourcing offshore non-core products: 
For non-core drugs BP1 sought solutions to reduce supply chain costs. The new strategy for 
BP1 was to use the cheaper Asian suppliers for non-core low tech, ‘simpler’ products, while 
sourcing core products from Western Europe for increased control and maximum quality 
assurance. BP1 decided not to keep non-core activities in house, especially those that involved 
simple chemistry, as it believed the quality of Asian suppliers would be acceptable, but the 
price comparatively lower. According to the Senior Director of SCM, India as an outsourcing 
location was not as attractive as China mainly due to lack of compliance and poor performance 
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of suppliers. In fact, during Phase III (2013-15) many orders had shifted to China from India. 
To reduce exogenous control disturbances, BP1 introduced robust audit processes to validate 
suppliers’ compliance with its ethical, safety, environmental and quality requirements. BP1 
was also following a multi-sourcing strategy while outsourcing offshore. As indicated by the 
Sourcing Director, policy is that two primary suppliers deliver two-thirds of its required 
capacity. Thus it was evident that BP1 was taking a more cautious, risk-averse approach to 
outsource offshoring and sought to ensure that it has a large enough supplier base for it non-
core products in the event of supply chain disturbances. 
5.2.3 Insourcing offshore 
In Phase III (2013-15), an interesting and unexpected phenomena started to occur – BP1 began 
insourcing offshore. BP1 was in the process of setting up what it called ‘captives’ both in 
Eastern Europe and Asia. These captives serve as an outreach independent businesses for BP1, 
with their individual bottom-line accountability and budget. The Global Outsourcing Manager 
explained the logic behind such a radical recalibration of the supply chain: “We used to 
outsource a lot of our products but due to lack of trust in suppliers….in the last two years things 
have changed, especially in procurement, supply chain and operations. The business models 
are evolving… This is a learning curve, a cycle – four years ago we were outsourcing 
everything to Asia, but now we are starting to use captives…In the longer term we would like 
to see standardisation, so want to keep similar suppliers.” 
One of the underlying objectives of having captives is to reduce the focal firm’s reliance 
on external partners. BP1 has offshore operations of its own, as well as offshore partners. By 
using such a hybrid model, BP1 aims to build the capabilities of its captives by absorbing the 
knowledge from its best outsourcing partners. Within two years BP1 expects its captives to 
develop their own capabilities. It then plans to slowly exit its external suppliers and focus 
business on the captives. This kind of insourcing offshore has a number of advantages. Namely, 
these captives help alleviate some of the control and cultural disturbances and more importantly 
mitigate IPR infringement risks that they are exposed to   with external suppliers. The captives 
are thus in essence an extension of the focal firm. According to the Global Outsourcing 
Manager, BP1 will be able to simplify, standardise and optimise its processes across the globe 
by developing such captives. This kind of supply chain configuration resembles a hub-and-
spoke model, where the Eastern European or Asian spokes drive efficiencies and the central 
Western European hubs drive innovation (R&D). 
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5.2.4 Supply chain disturbance framework 
Resulting from the literature review and our findings, we constructed the Supply Chain Disturbance Framework (Figure 7). Here we identify supply 
chain-wide disturbances of a Western European-based BP in relation to the three possible supply chain configurations. The framework is developed 
to account for disturbances (risk and uncertainty) caused by factors internal and external to the focal firm. The Supply Chain Disturbance 
Framework incorporates firm-, network- and site-related disturbance factors and their potential impact on different supply chain configurations. 
This requires reconfiguring the supply chain in order to keep pace with the changing environment. We assert that supply chain disturbance factors 
affect particular configurations in different ways, which in turn are mitigated through different reconfiguration strategies.  
 
 
Figure 7: The Supply Chain Disturbance Framework 
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6. Conclusions 
In this paper, different supply chain configuration strategies for Western European 
pharmaceutical firms are explored and a framework is developed to assess the level of 
disturbance factors associated with, outsourcing to and/or locating manufacturing operations 
in, three major regions: Western Europe, Eastern Europe and Asia. Through a multi-phase, 
mixed-method approach carried out, over a period of five years, we find that the top five 
disturbance factors managers should be aware of while configuring their supply chains are 
quality defects, unforeseen and random interruptions in manufacturing processes, order 
processing difficulties, untimely delivery of products, and a mismatch between market demand 
and supplier responsiveness. Interestingly, a number of novel factors were also identified. For 
example, our results demonstrated that quality defects represent the top disturbance factor for 
Western and Eastern Europe. This shows that the cost of quality defects has implications all 
along the supply chain, especially given the critical nature of pharmaceutical products. The 
reason for ranking quality disturbances the highest in Western Europe perhaps reflects the 
stricter standards by both consumers and regulatory bodies as well as the potentially grave 
negative impacts on the business. A further counterintuitive finding was that communication 
problems were ranked quite high (4th) within Western Europe. This suggests that there can still 
be miscommunication and misunderstandings even when suppliers/manufacturing units are 
closer to home. Our data analysis also provides a nuanced view of how these disturbances differ 
in different countries within regions e.g. higher cultural disparity and greater difficulties in 
transmission of data in India caused BP1 to shift their orders. 
Most previous studies on supply chain design and disturbances have explored how 
supply chain design characteristics affect the degree of supply chain disruptions (Craighead et 
al., 2007). Even recently, Habermann et al. (2015) investigated supply chain disturbances in 
co-located and dispersed supply chain designs and found that co-location with suppliers is 
related to shorter duration of disruptions. However, the study of the effect of disturbances on 
supply chain design, and supply chain re-configuration as a disturbance mitigating strategy is 
relatively unexplored. Our findings show that in this era of increased potential disturbances, it 
is not enough to just consider between alternative design strategies, rather firms need to be 
flexible and adaptable (Christopher and Holweg, 2011). Interestingly, we found empirical 
evidence of supply chain disturbances influencing firms to bring production back home 
(reshoring) or to a closer location (near-shoring). The underlying reasons for reconfiguring 
supply chain strategies included both exogenous disturbance factors (e.g. the Tianjin explosion 
in China, which had detrimental effect on SC performance) and endogenous disturbance factors 
(e.g. lack of data integrity - a supplier falsifying environmental data). 
6.1 Managerial implications 
This research offers useful insights for managers by providing a detailed conceptual framework 
of the supply chain disturbance constructs. Furthermore, the study highlights how important it 
is for the focal pharmaceutical firms to understand that disturbances can occur at all levels 
within the supply network. By being aware of the key disturbance factors in different supply 
chain configurations, managers will be better equipped to predict the challenges they are likely 
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to face, allowing them to either avoid or overcome them. For example, to mitigate the effects 
of disturbances, firms can recalibrate their supply chain configurations by insourcing core 
products, outsourcing non-core products offshore and developing offshore insourcing 
capabilities through ‘captives’. These findings can be generalised to an extent to other similar 
industries, for instance the food industry where certain disturbances affecting the supply chain 
can also potentially threaten consumers’ lives e.g. the 2008 contamination of milk products 
with melamine in China, which sickened thousands and led to the death of six babies. 
Therefore, repercussions of such critical consequences is forcing managers to rethink their 
supply chain configuration and this study will help them deploy appropriate strategies to 
mitigate disturbances.   
6.2 Limitations and Future Research 
Although this study is based on insights from the pharmaceutical industry, non-industry 
specific elements (e.g. majority of the disturbance factors) can be applied and extended to other 
sectors. However, it should be taken into account that there is no ‘one-size-fits-all’ strategy, 
and even in firms in similar sectors supply chain design differs, owing to unique characteristics. 
Therefore, it is important to note that some of the supply chain configurations presented in this 
paper would not be appropriate for particular drug types and that the locations suggested might 
in certain cases not be feasible due to regulatory issues. Thus, other measures may be relevant 
and should be considered by firms and supply chain participants to reflect their unique needs. 
 Through this longitudinal multi-phase, mixed methods study, the dynamic nature of the 
pharmaceutical industry has been highlighted. Our findings show how supply chain 
disturbances lead to a change in strategies at the macro level (reconfigurations). However, the 
effect of disturbances at the micro level, in particular on supply chain performance metrics has 
not been addressed. Therefore, there remains a need for additional empirical research on how 
disturbance factors impact the performance of the supply chain configurations (e.g. in terms of 
lead time, inventory, quality, flexibility, customer responsiveness and cost). This research 
provides a base for systems modellers, who, if given access to appropriate data, can begin the 
task of developing more complete predictive simulations of the likely effects of disturbances 
on the performance of different supply chain configurations. It would also be interesting to 
examine how supply chain reconfiguration compares with other risk mitigation strategies (e.g. 
product management, process improvements, supply chain integration, capital adequacy etc.). 
Once developed, these models could provide assistance for managers and policy makers. 
Further research could also focus on conducting in-depth multi-tier case studies in additional 
industry sectors and evaluate the importance of each disturbance factor with respect to different 
supply chain configurations through Analytic Hierarchy Process or Analytic Network Process 
methods.  
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